Traditional Chinese medicine composition for treating allergic asthma and preparation method thereof

Abstract

The invention discloses a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, and the traditional Chinese medicine composition comprises the following components in parts by weight: 2-10 parts of honey-fried ephedra, 3-10 parts of scutellaria baicalensis, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae nipponicae, 5-10 parts of scalded semen armeniacae amarae, 2-10 parts of liquorice, 3-10 parts of fried fructus perillae, 3-9 parts of fried semen brassicae, 5-10 parts of schizonepeta, 3-10 parts of platycodon grandiflorum and 5-12 parts of fried semen raphani. The pharmaceutical composition disclosed by the invention is a pure traditional Chinese medicine preparation, and can be used for reducing the level of eosinophilic granulocytes, increasing the number of alveolar macrophages and effectively improving abnormal immune response in an asthma process; lesion degrees such as lung tissue inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia are relieved; secretion of Th2 type inflammatory cell related factors and IgE is reduced, and finally the effect of treating allergic asthma inflammatory response is achieved.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof. Background Art

[0002] Bronchial asthma is a common chronic airway inflammatory disease. Among the clinical phenotypes of asthma, allergic asthma is the most easily recognizable and has a relatively high incidence rate, accounting for more than 50% of adult asthma and up to more than 80% in childhood asthma. Allergic asthma is a type of asthma induced by allergens such as dust mites, fungi, pollen, and animal dander, mainly mediated by Th2-type inflammatory factors and IgE. Currently, the drugs commonly used in clinical treatment of allergic asthma mainly include long-acting β2 receptor agonists, inhaled corticosteroids, leukotriene receptor antagonists, etc.

[0003] From the perspective of traditional Chinese medicine, asthma belongs to the categories of "wheezing disorder", "dyspnea syndrome", "cough", etc. The basic pathogenesis is that the body is deficient in essence, especially the lungs are weak, phlegm blocks the airway, and the lungs fail to disperse and descend. In treatment, traditional Chinese medicine emphasizes treatment based on different stages. In the acute attack stage, expelling pathogenic factors takes precedence, resolving phlegm, relieving asthma, and relieving cough to treat the symptoms. In the remission stage, strengthening the healthy qi is the main point, and attention is paid to regulating and tonifying the lungs, spleen, and kidneys, and removing stubborn phlegm to treat the root cause. According to the etiology and pathogenesis of asthma, the traditional Chinese medicines for treating asthma are mainly phlegm-resolving, cough-suppressing, asthma-relieving, tonifying deficiency, exterior-releasing, and heat-clearing drugs. Modern research has confirmed that traditional Chinese medicine can effectively regulate the immune function of asthma, relieve airway inflammatory reactions, and has obvious advantages in improving the curative effect and adverse reactions. Chinese Patent CN109394862A discloses a traditional Chinese medicine composition for treating bronchial asthma, which is composed of six traditional Chinese medicines such as cicada slough, fluorite, bitter apricot kernels, etc.; Chinese Patent CN111467443A discloses a traditional Chinese medicine compound preparation prepared from eight traditional Chinese medicines such as pilose antler, ophiopogon root, coix seed, etc., which is used for treating the remission stage of asthma.

[0004] Currently, the drugs commonly used in clinical treatment of allergic asthma, such as corticosteroids, although having characteristics such as quick onset of effect, have disadvantages such as many adverse reactions and high drug resistance when used for a long time. In recent years, although great progress has been made in the research and development of biological targeted drugs for asthma, there are deficiencies such as high treatment costs and limited applicable populations. In addition, the existing traditional Chinese medicine compositions for treating asthma also have certain limitations, such as long treatment cycles, poor curative effects, poor patient compliance, etc., and among the publicly disclosed patents, there are few traditional Chinese medicine compositions specifically targeting allergic asthma. Summary of the Invention

[0005] The purpose of the present invention is to provide a traditional Chinese medicine composition for treating allergic asthma and a preparation method thereof, so as to solve the problems raised in the above background art.

[0006] To achieve the above purpose, the present invention provides the following technical solutions:

[0007] The traditional Chinese medicine composition for treating allergic asthma of the present invention is a medicament prepared from raw medicinal materials in the following weight ratios: 2 - 10 parts of honey-fried ephedra, 3 - 10 parts of scutellaria baicalensis, 9 - 15 parts of momordica grosvenori, 9 - 15 parts of dioscorea nipponica, 5 - 10 parts of blanched bitter apricot kernels, 2 - 10 parts of liquorice, 3 - 10 parts of stir-fried perilla seeds, 3 - 9 parts of stir-fried white mustard seeds, 5 - 10 parts of schizonepeta tenuifolia, 3 - 10 parts of platycodon grandiflorum, 5 - 12 parts of stir-fried radish seeds.

[0008] Based on the understanding of the pathogenesis and treatment principles of asthma in traditional Chinese medicine, combined with the results of modern pharmacological research, the present invention is formulated according to the principle of dispersing the lung qi to relieve the exterior syndrome, resolving phlegm, relieving cough and asthma. Among them, ephedra, apricot kernels and perilla seeds are the monarch drugs, radish seeds and white mustard seeds are the ministerial drugs, dioscorea nipponica, scutellaria baicalensis, schizonepeta tenuifolia, platycodon grandiflorum and momordica grosvenori are the adjuvant drugs, and liquorice is the guiding drug. Ephedra is the first drug for treating asthma, which is good at relieving exterior cold and dispersing the lung qi to relieve asthma; apricot kernels lower and promote the qi of the lung, and also have the function of dispersing and promoting, which is combined with ephedra, one dispersing and one descending, to regulate the stagnation of the lung qi; perilla seeds descend qi and resolve phlegm, enhancing the effect of apricot kernels in descending qi, and jointly achieving the effect of resolving phlegm and relieving asthma. Radish seeds lower qi and remove phlegm, and are also good at promoting digestion and guiding stagnation; white mustard seeds warm the lung and resolve phlegm; the two jointly assist the monarch drugs in eliminating phlegm and guiding stagnation. Scutellaria baicalensis clears the lung and purges fire, dries dampness and resolves phlegm. The combination of scutellaria baicalensis and ephedra combines pungency and bitterness, and combines cold and warmth, balancing the properties of the whole formula; schizonepeta tenuifolia relieves the exterior syndrome and disperses wind; platycodon grandiflorum relieves sore throat and discharges pus; dioscorea nipponica, combined with ephedra and apricot kernels, relieves cough and asthma; momordica grosvenori clears heat and moistens the lung, and at the same time has the effect of correcting the taste; liquorice harmonizes all the drugs. The whole formula is used in combination, with the combination of dispersion and descent, the combination of warming and clearing, the treatment of phlegm and qi simultaneously, and the treatment of exterior and interior syndromes simultaneously, achieving the effect of dispersing the lung qi to relieve the exterior syndrome, resolving phlegm, relieving cough and asthma, which conforms to the theoretical principle of "driving out pathogenic factors first, resolving phlegm, relieving asthma and cough to treat the symptoms" in traditional Chinese medicine for the acute attack period of asthma.

[0009] Further preferably, the traditional Chinese medicine composition for treating allergic asthma includes: 10 parts of honey-fried ephedra, 8 parts of scutellaria baicalensis, 9 parts of momordica grosvenori, 12 parts of dioscorea nipponica, 10 parts of blanched bitter apricot kernels, 6 parts of liquorice, 8 parts of stir-fried perilla seeds, 8 parts of stir-fried white mustard seeds, 5 parts of schizonepeta tenuifolia, 5 parts of platycodon grandiflorum, 8 parts of stir-fried radish seeds, by weight.

[0010] The preparation method of the traditional Chinese medicine composition for treating allergic asthma of the present invention from the above components includes the following steps:

[0011] S01. Weigh the raw Chinese medicinal materials according to the above dosages.

[0012] S02. Add water 10 times the weight of the drug and soak for 30 minutes.

[0013] S03. Heat and decoct for extraction for 1.5 hours, filter, and collect the filtrate.

[0014] S04. Add 8 times the amount of water to the filter residue and decoct for extraction for 1 hour, filter, and combine the two filtrates to obtain the total extract.

[0015] S05. Concentrate the total extract under reduced pressure into an extract with a relative density of 1.10 - 1.20.

[0016] The present invention also provides an application of the traditional Chinese medicine composition as described above in the medicament for treating allergic asthma.

[0017] The extract of the present invention can be made into any clinically acceptable dosage form through conventional traditional Chinese medicine preparation processes, such as tablets, pills, capsules, granules, oral liquids, etc.

[0018] Compared with the prior art, the beneficial effects of the present invention are as follows:

[0019] The pharmaceutical composition of the present invention is a pure traditional Chinese medicine preparation. After the compatibility of each raw material, it can down-regulate the level of eosinophils, and at the same time increase the number of alveolar macrophages, effectively improving the abnormal immune response during asthma; reducing the degree of pathological changes such as inflammatory cell infiltration, alveolar wall edema and goblet cell hyperplasia in the lung tissue; reducing the secretion of Th2-type inflammatory cell-related factors and IgE, and ultimately achieving the effect of treating the inflammatory reaction of allergic asthma. Description of the Drawings

[0020] Figure 1 For the classification and counting results of macrophages (Mac), eosinophils (Eos) and lymphocytes (Lym) in BALF ( ## p < 0.01 compared with the normal group; * p < 0.05, ** p < 0.01 compared with the model group);

[0021] Figure 2 For the HE staining results of lung tissue pathological sections of mice in each group;

[0022] Figure 3 For the IgE content in the sera of mice in each group ( ## p < 0.01 compared with the normal group; * p < 0.05, ** p < 0.01 compared with the model group);

[0023] Figure 4 For the IL-4 content in BALF of mice in each group ( ## p < 0.01 compared with the normal group; * p < 0.05, ** p < 0.01 compared with the model group);

[0024] Figure 5 For the expression of mRNA of IL-4, IL-5 and IL-13 in the lung tissues of mice in each group ( # p < 0.05, ## p < 0.01 compared with the normal group; * p < 0.05, ** p < 0.01 compared with the model group). Detailed implementation manners

[0025] The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts shall fall within the protection scope of the present invention.

[0026] Example 1

[0027] 1. Weigh the following raw medicinal materials: honey-fried Ephedra 10 g, Scutellaria baicalensis 8 g, Momordica grosvenori 9 g, Dioscorea nipponica 12 g, blanched bitter apricot kernels 10 g, Glycyrrhiza uralensis 6 g, stir-fried Perilla seeds 8 g, stir-fried white mustard seeds 8 g, Schizonepeta tenuifolia 5 g, Platycodon grandiflorum 5 g, stir-fried Raphanus sativus seeds 8 g.

[0028] 2. Add water 10 times the weight of the drug and soak for 30 minutes;

[0029] 3. Heat and decoct for extraction for 1.5 hours, filter, and collect the filtrate;

[0030] 4. Add 8 times the amount of water to the filter residue and decoct for extraction for 1 hour, filter, and combine the two filtrates to obtain the total extract;

[0031] 5. Concentrate the total extract under reduced pressure into an extract with a relative density of 1.10 - 1.20.

[0032] Example 2

[0033] 1. Weigh the following raw medicinal materials: honey-fried Ephedra 10 g, Scutellaria baicalensis 10 g, Momordica grosvenori 9 g, Dioscorea nipponica 15 g, blanched bitter apricot kernels 10 g, Glycyrrhiza uralensis 6 g, stir-fried Perilla seeds 8 g, stir-fried white mustard seeds 8 g, Schizonepeta tenuifolia 5 g, Platycodon grandiflorum 5 g, stir-fried Raphanus sativus seeds 8 g.

[0034] 2. Add water 10 times the weight of the drug and soak for 30 minutes;

[0035] 3. Heat and decoct for extraction for 1.5 hours, filter, and collect the filtrate;

[0036] 4. Add 8 times the amount of water to the filter residue and decoct for extraction for 1 hour, filter, and combine the two filtrates to obtain the total extract;

[0037] 5. Concentrate the total extract under reduced pressure into an extract with a relative density of 1.10 - 1.20.

[0038] Example 3

[0039] 1. Weigh the following raw materials of traditional Chinese medicine: 5 g of honey-fried Ephedra, 8 g of Scutellaria baicalensis, 9 g of Siraitia grosvenorii, 9 g of Dioscorea nipponica, 5 g of bitter apricot kernels processed by blanching, 6 g of Glycyrrhiza uralensis, 8 g of stir-fried Perilla seeds, 8 g of stir-fried Brassica alba seeds, 5 g of Schizonepeta tenuifolia, 5 g of Platycodon grandiflorum, 8 g of stir-fried Raphanus sativus seeds.

[0040] 2. Add water 10 times the weight of the medicine and soak for 30 minutes;

[0041] 3. Heat and decoct for extraction for 1.5 hours, filter, and collect the filtrate;

[0042] 4. Add 8 times the amount of water to the filter residue and decoct for extraction for 1 hour, filter, and combine the two filtrates to obtain the total extract;

[0043] 5. Concentrate the total extract under reduced pressure into an extract with a relative density of 1.10 - 1.20.

[0044] Example 4

[0045] 1. Weigh the following raw materials of traditional Chinese medicine: 10 g of honey-fried Ephedra, 8 g of Scutellaria baicalensis, 9 g of Siraitia grosvenorii, 12 g of Dioscorea nipponica, 10 g of bitter apricot kernels processed by blanching, 6 g of Glycyrrhiza uralensis, 8 g of stir-fried Perilla seeds, 8 g of stir-fried Brassica alba seeds, 5 g of Schizonepeta tenuifolia, 5 g of Platycodon grandiflorum, 8 g of stir-fried Raphanus sativus seeds.

[0046] 2. Add water 10 times the weight of the medicine and soak for 30 minutes;

[0047] 3. Heat and decoct for extraction for 1.5 hours, filter, and collect the filtrate;

[0048] 4. Add 8 times the amount of water to the filter residue and decoct for extraction for 1 hour, filter, and combine the two filtrates to obtain the total extract;

[0049] 5. Concentrate the total extract under reduced pressure into an extract with a relative density of 1.10 - 1.20;

[0050] In other embodiments of the present invention, the obtained extract is made into tablets, pills, capsules, granules, oral liquids, etc. by common processes.

[0051] Example 5

[0052] 1. Experimental method

[0053] 1.1 Experimental animals and grouping

[0054] 1.1.1 Experimental animals: 60 SPF-grade C57BL / 6J female mice, 6 - 8 weeks old, weighing 16 - 18 g, purchased from Shanghai Slac Laboratory Animal Co., Ltd. The mice were housed in cages in the barrier system of the Experimental Animal Center of China Pharmaceutical University. The indoor temperature was 23 ± 2 °C, the humidity was 55 ± 5%, and a 12 h light / dark cycle was adopted, with free access to water and food. Animal ethics and all experimental operations were approved by the Animal Ethics Committee of China Pharmaceutical University.

[0055] 1.1.2 Grouping: After one week of adaptive feeding, 60 mice were randomly divided into a blank group (Control), an asthma model group (Asthma), a low-dose composition group (WAHSZ-L, 19.34 g / kg / d), a medium-dose composition group (WAHSZ-M, 38.68 g / kg / d), a high-dose composition group (WAHSZ-H, 77.35 g / kg / d), and a positive drug dexamethasone group (DXM, 1 mg / kg / d), with 10 mice in each group.

[0056] 1.2 Reagent preparation

[0057] ① House dust mite (HDM) solution: Using physiological saline, prepare a solution of 0.2 μg / μL according to the dry weight, and dispense it for use at -20°C.

[0058] ② 1% pentobarbital sodium solution: Weigh an appropriate amount of pentobarbital sodium and add physiological saline to prepare a working solution of 10 mg / mL.

[0059] ③ Dexamethasone solution: Weigh an appropriate amount of dexamethasone and add physiological saline to prepare a working solution of 0.2 mg / mL.

[0060] 1.3 Establishment of an HDM-induced asthma model

[0061] Except for the blank group, all groups were induced with an asthma model using HDM on days 0, 3, 5, 10, 12, and 14. The specific operation is as follows: Intraperitoneally inject 100 μL of 1% pentobarbital sodium solution. After the mice are anesthetized, take 50 μL of the HDM solution for double sensitization by nasal drip and tracheal instillation. Starting from day 0 of modeling, continuously administer the traditional Chinese medicine composition extract prepared in Example 1 by gavage, and the positive drug dexamethasone starts continuous intraperitoneal injection on day 10. The animals were sacrificed and samples were taken on day 16.

[0062] 1.4 Collection and processing of samples

[0063] ① Serum: After fasting the mice for 12 h, collect blood by eye socket puncture, let it stand for 30 min, and centrifuge at 3000 rpm for 20 min. The obtained serum was stored at -80°C.

[0064] ② Bronchoalveolar lavage fluid (BALF): After decapitating the mice, separate and expose the trachea from the neck to make a transverse incision, ligate the trachea and insert a tracheal intubation needle, and repeatedly lavage 3 times with 0.8 mL of pre-cooled PBS to ensure a recovery rate of more than 80%. The collected BALF was centrifuged at 2000 rpm for 5 min at 4°C. The precipitate was used for cell counting, and the supernatant was used for the detection of inflammatory factors.

[0065] ③ Lung tissue: Dissect the thoracic cavity longitudinally along the neck to expose the heart and lungs. Take the upper right lobe of the lung and fix it in 4% paraformaldehyde fixative for H&E staining. The remaining lung tissue is stored at -80 °C.

[0066] 1.5 Index detection

[0067] 1.5.1 Differential cell count in BALF

[0068] Add 15 μl of PBS to the precipitate, resuspend it by pipetting, transfer 10 μl and spot it at the center of a glass slide. After air-drying in a fume hood, perform Wright-Giemsa staining. Add 150 μl of Solution A to each glass slide and stain for 1 min. Then add 450 μl of Solution B and gently blow the liquid surface with an ear syringe until a golden film can be observed on the surface. Time for 10 min, then gently rinse with water for 15 s and air-dry. Count at least 200 cells under an upright microscope. Classify the cells into eosinophils, macrophages, lymphocytes, etc. according to morphological characteristics, and analyze the types and proportion changes of inflammatory cells in the BALF of each group of mice.

[0069] 1.5.2 H&E staining of lung tissue

[0070] Fix the lung tissue in 4% paraformaldehyde solution for 24 h and then embed it in paraffin. After embedding, cut sections. Place the sections in xylene to dewax, then soak them in 100%, 95%, and 80% ethanol for 5 min respectively, and finally rinse with distilled water. Then stain in hematoxylin staining solution for 5 - 10 min and thoroughly wash with water to blue. Then stain in eosin for 2 min, then soak in 80%, 95%, and 100% ethanol for 5 min respectively, then soak in xylene, and finally mount with neutral balsam. Use a slide scanner to scan and observe the sections.

[0071] 1.5.3 ELISA to detect the levels of IgE in mouse serum and IL-4 in BALF

[0072] Detect the contents of IgE in mouse serum and IL-4 in BALF according to the instructions of the ELISA kit of Xinbosheng Biotechnology Co., Ltd.; after taking out the detection kit, equilibrate it at room temperature for 20 min. Respectively set up standard wells, blank wells and sample wells. Among them, add 100 μL of standard products with different concentrations to each well in the standard well, add 100 μL of sample diluent to the blank well, and add 100 μL of diluted sample to each well in the sample well. Seal the reaction wells with a sealing plate film and incubate at 37 °C for 90 min, discard the liquid and pat dry on the absorbent paper, add full washing solution to each well and let it stand for 1 min, repeat the washing 5 times. Then, add 100 μL of biotinylated antibody working solution to all wells, react at 37 °C for 60 min, and wash the plate 5 times as above. Then add 100 μL of enzyme conjugate working solution and react at 37 °C for 30 min. After repeating the washing 5 times, add 100 μL of chromogenic substrate (TMB), incubate at 37 °C in the dark for 15 min. Finally, add 100 μL of reaction termination solution, and detect the absorbance value of each well with an enzyme-linked immunosorbent assay (ELISA) reader within 5 min, and the detection wavelength is 450 nm.

[0073] 1.5.4 RT-qPCR detection of the mRNA levels of IL-4, IL-5, and IL-13 in lung tissues

[0074] ① Sample preparation: Randomly select three samples from each group, cut lung tissues of the same mass (30 mg) into 1.5 mL RNase-free centrifuge tubes.

[0075] ② Total RNA extraction: Operate according to the instructions of the SteadyPure Universal RNA Extraction Kit of Aikerui Biotechnology Co., Ltd.: Add 600 μL of lysis buffer Buffer RLS and two sterilized and nuclease-free grinding beads to each sample, and grind thoroughly in a grinder. After the lysis buffer stands at room temperature for 2 minutes, centrifuge at 12,000 rpm at 4 °C for 5 minutes, and aspirate the supernatant to a new 1.5 mL RNase-free centrifuge tube. For the purification steps, use the gDNA Eraser Mini Column to remove gDNA, the Universal RNA Mini Column to adsorb RNA, wash once with 600 μL of Buffer RWA, and wash twice with 650 μL of Buffer RWB. Finally, elute the RNA with 50 μL of RNase Free water.

[0076] ③ RNA concentration and purity detection: After calibrating the Nano-100 ultra-micro spectrophotometer with 1 μL of DEPC water for blank, take 1 μL of the RNA test solution for sample loading and testing, and record the RNA concentration in the sample. Evaluate the purity of RNA with the ratios of 260 / 280 (1.8 - 2.0) and 260 / 230 (1.8 - 2.2).

[0077] ④RNA reverse transcription: Calculate the RNA dilution volume based on a loading amount of 800 ng. Prepare a 20 μL reaction system according to the instruction manual of the Evo M-MLV Reverse Transcription Premix Kit from Aikrui Biotechnology Co., Ltd., as shown in Table 1. Vortex the reaction system thoroughly and then centrifuge it instantaneously at 3000 rpm. Reverse transcribe to obtain cDNA according to the reaction procedure of the kit.

[0078] Table 1 Reverse transcription reaction system

[0079] Component Reaction volume 5XHiScriptII qRT SuperMix II 4 μL Total RNA Appropriate amount <![CDATA[RNase-free ddH2O]]> to 20 μL

[0080] ⑤Real-time PCR: Prepare a 20 μL reaction system (cDNA: Mix: forward primer: reactant: DEPC water = 1:10:0.4:0.4:8.2) according to the instruction manual of ChamQ qPCR Master Mix (Aikrui Biotechnology Co., Ltd.). The primer sequences are shown in Table 2. Set the amplification program according to the instruction manual. Finally, calculate the relative mRNA levels in each group of samples using the 2-ΔΔCT algorithm with β-actin as the internal reference.

[0081] Table 2 Primer sequences

[0082]

[0083] 1.5.5 Statistical analysis

[0084] The experimental data were statistically analyzed using GraphPad Prism 10.1.2 software, and the results were expressed as Mean ± SD. Unpaired two-tailed Student's t-test (for two groups of data) or ANOVA combined with Kruskal-Wallis test (for multiple groups of data) was used for significant analysis between groups. P < 0.05 indicates significant difference.

[0085] 2. Experimental results

[0086] 2.1 Statistical analysis of cell differential count in BALF

[0087] The Th2-type specific immune response is mediated by eosinophils. Compared with the blank group, the proportion of macrophages in the BALF of mice in the model group decreased significantly, while the proportion of eosinophils increased significantly; compared with the model group, the proportion of macrophages in each drug administration group increased significantly, while the proportion of eosinophils decreased significantly. There was no significant difference in the proportion of lymphocytes in each group. The specific results are shown in the appendix Figure 1 . It shows that this traditional Chinese medicine composition can effectively improve the abnormal immune response in the lungs induced by HDM.

[0088] 2.2 Results of HE staining of lung tissue

[0089] HE staining of the lung tissues of mice in each group showed that compared with the blank group, the model group showed obvious inflammatory response, exudates in the bronchial cavity, and obvious inflammatory cell infiltration around the bronchi. Compared with the model group, the inflammatory response was significantly reduced in both the Chinese medicine group and the positive drug group. The specific results are shown in the attached Figure 2 As shown, it is suggested that the Chinese medicine composition can alleviate lung inflammation in asthmatic mice.

[0090] 2.3 Effect of Chinese herbal medicine combination on serum IgE levels in asthmatic mice

[0091] As a key intermediate product and biomarker of allergic inflammatory diseases, IgE is one of the key indicators of allergic asthma. Figure 3 As shown, compared with the blank group, the IgE concentration in the serum of the mice in the model group was significantly increased, while the IgE level in the serum of the mice in the Chinese medicine administration group and the positive drug group was significantly decreased, indicating that the Chinese medicine composition has a mitigating effect on allergic reactions.

[0092] 2.4 Effect of Chinese herbal medicine combination on IL-4 level in BALF of asthmatic mice

[0093] Allergic asthma is an immune inflammation mediated by Th2, which is specifically manifested by the massive secretion of type 2 inflammatory cytokines. IL-4 is secreted by Th2 cells and can activate B cells, thereby releasing IgE and promoting airway inflammation. ELISA results showed that compared with the blank group, the IL-4 level in the BALF of the model group mice was significantly increased, while the IL-4 level in each group decreased significantly after administration. Specific results are shown in the attached Figure 4 .

[0094] 2.5 Effect of Chinese herbal medicine combination on IL-4, IL-5, and IL-13 mRNA expression in lung tissue of asthmatic mice

[0095] The qPCR technique was used to detect the mRNA expression levels of type 2 inflammatory cytokines IL-4, IL-5, and IL-13 in the lung tissues of mice. It was found that both the Chinese medicine composition and dexamethasone intervention could significantly inhibit the mRNA expression of Th2 cytokines induced by HDM, relieve the airway inflammatory response of asthma from the transcription level of inflammatory factors, and the efficacy of the Chinese medicine composition was stronger than dexamethasone. Specific results are shown in the attached Figure 5 .

[0096] It should be noted that in this text, relational terms such as first and second are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any actual relationship or order between these entities or operations. Moreover, the term "comprising", "including" or any other variant thereof is intended to cover non-exclusive inclusion, so that a process, method, article or device comprising a series of elements not only includes those elements, but also includes other elements not expressly listed, or further includes elements inherent to such process, method, article or device.

[0097] It should be noted that the above content only illustrates the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. For those of ordinary skill in the art, without departing from the principle of the present invention, several improvements and refinements can be made, and these improvements and refinements all fall within the protection scope of the claims of the present invention.

Claims

1. A traditional Chinese medicine composition for treating allergic asthma, characterized in that, By weight, it includes 2-10 parts of honey ephedra, 3-10 parts of scutellaria, 9-15 parts of momordica grosvenori, 9-15 parts of rhizoma dioscoreae, 5-10 parts of stewed bitter almonds, 2-10 parts of licorice, 3-10 parts of stir-fried perilla seeds, 3-9 parts of stir-fried white mustard seeds, 5-10 parts of schizonepeta, 3-10 parts of platycodon, and 5-12 parts of stir-fried radish seeds.

2. The traditional Chinese medicine composition for treating allergic asthma according to claim 1, wherein, Calculated by weight, it includes 10 parts of honey ephedra, 8 parts of scutellaria, 9 parts of momordica grosvenori, 12 parts of rhizoma dicae, 10 parts of stewed bitter almonds, 6 parts of licorice, 8 parts of stir-fried perilla seeds, 8 parts of stir-fried white mustard seeds, 5 parts of schizonepeta, 5 parts of platycodon, and 8 parts of stir-fried radish seeds.

3. The preparation method of a traditional Chinese medicine composition for treating allergic asthma according to any one of claims 1-2, characterized in that, The preparation method comprises the following steps: S01. Weigh the raw Chinese medicinal materials according to the amount described in claim 1 or 2; S02, add 10 times the weight of the drug in water and soak for 30 minutes; S03, heating and boiling for 1.5 hours, filtering, and collecting the filtrate; S04, add 8 times the amount of water to the filter residue and boil for 1 hour, filter, and combine the two filtrates to obtain the total extract; S05. Concentrate the total extract under reduced pressure to form an extract with a relative density of 1.10 to 1.

20.

4. Use of the Chinese medicine composition according to any one of claims 1 to 2 in the treatment of allergic asthma.

Images